The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...